Core Insights - The PatentVest Pulse report highlights the competitive landscape of oral small-molecule GLP-1 drugs, emphasizing the importance of patent strength and clinical efficacy in determining long-term market success [1][2][4]. Industry Overview - The GLP-1 drug market has reached a valuation of $71 billion, with injectable forms currently serving less than 5% of eligible patients, indicating significant growth potential for oral alternatives [1]. - Over 50 oral small-molecule programs are in development, aiming to capture the remaining 95% of the market [1]. Patent Analysis - The report analyzes over 1,200 patent documents across 26 clinical-stage programs, revealing significant disparities in patent depth among programs at similar development stages [2]. - Key factors in patent defensibility include composition-of-matter claims, Markush scope, formulation layers, and method-of-use protection [2]. Market Dynamics - Since 2023, more than $47 billion in GLP-1-related deal value has been committed, yet many oral programs remain unpartnered [3]. - The impending patent expirations for semaglutide in 2031 and tirzepatide in 2036 will create pressure for early generic competition, making long-term exclusivity critical for market positioning [3]. Competitive Landscape - The analysis includes 50 oral small-molecule GLP-1 programs globally, with a focus on 30 in clinical development, assessing the intellectual property positioning of major players such as Eli Lilly, Novo Nordisk, Pfizer, Roche, AstraZeneca, and Gilead [4]. - The competitive advantage may hinge on the breadth of patent claims, with broader genus claims potentially offering more substantial market control over the next two decades [4].